Comparing serum protein levels can aid in differentiating HPV-negative and -positive oropharyngeal squamous cell carcinoma patients

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/317819

Lähdeviite

Dickinson , A , Saraswat , M , Syrjänen , S , Tohmola , T , Silén , R , Randén-Brady , R , Carpén , T , Hagström , J , Haglund , C , Mattila , P , Mäkitie , A , Joenväärä , S & Silén , S 2020 , ' Comparing serum protein levels can aid in differentiating HPV-negative and -positive oropharyngeal squamous cell carcinoma patients ' , PLoS One , vol. 15 , no. 6 , 0233974 . https://doi.org/10.1371/journal.pone.0233974

Julkaisun nimi: Comparing serum protein levels can aid in differentiating HPV-negative and -positive oropharyngeal squamous cell carcinoma patients
Tekijä: Dickinson, Amy; Saraswat, Mayank; Syrjänen, Stina; Tohmola, Tiialotta; Silén, Robert; Randén-Brady, Reija; Carpén, Timo; Hagström, Jaana; Haglund, Caj; Mattila, Petri; Mäkitie, Antti; Joenväärä, Sakari; Silén, Suvi
Tekijän organisaatio: Department of Ophthalmology and Otorhinolaryngology
University of Helsinki
Helsinki University Hospital Area
Research Program in Systems Oncology
Research Programs Unit
Faculty of Medicine
HUSLAB
Transplantation Laboratory
Department of Pathology
Medicum
HUS Head and Neck Center
Department of Surgery
HUS Abdominal Center
II kirurgian klinikka
CAN-PRO - Translational Cancer Medicine Program
Korva-, nenä- ja kurkkutautien klinikka
Clinicum
Päiväys: 2020-06-15
Kieli: eng
Sivumäärä: 13
Kuuluu julkaisusarjaan: PLoS One
ISSN: 1932-6203
DOI-tunniste: https://doi.org/10.1371/journal.pone.0233974
URI: http://hdl.handle.net/10138/317819
Tiivistelmä: Background The surrogate immunohistochemical marker, p16INK4a, is used in clinical practice to determine the high-risk human papillomavirus (HPV) status of oropharyngeal squamous cell carcinomas (OPSCC). With a specificity of 83%, this will misclassify some patients compared with direct HPV testing. Patients who are p16INK4a-positive but HPV DNA-negative, or RNA-negative, may be unsuitable for treatment de-escalation aimed at reducing treatment-related side effects. We aimed to identify cost-effective serum markers to improve decision making for patients at risk of misclassification by p16INK4a alone. Methods Serum proteins from pre-treatment samples of 36 patients with OPSCC were identified and quantified using label-free mass spectrometry-based proteomics. HPV-status was determined using p16INK4a/HPV DNA and E6/E7 mRNA. Serum protein expressions were compared between groups of patients according to HPV status, using the unpaired t-test with a Benjamini-Hochberg correction. ROC curves (AUC) were calculated with SPSS (v25). Results Of 174 serum proteins identified, complement component C7 (C7), apolipoprotein F (ApoF) and galectin-3-Binding Protein (LGALS3BP) significantly differed between HPV-positive and -negative tumors (AUC ranging from 0.84–0.87). ApoF levels were more than twice as high in the E6/E7 mRNA HPV-positive group than HPV-negative. Conclusions Serum C7, ApoF and LGALS3BP levels discriminate between HPV-positive and HPV-negative OPSCC. Further studies are needed to validate these host immunity-related proteins as markers for HPV-associated OPSCC.
Avainsanat: 3122 Cancers
3125 Otorhinolaryngology, ophthalmology
HUMAN-PAPILLOMAVIRUS
DIAGNOSTIC-ACCURACY
CANCER
HEAD
SURVIVAL
METASTASIS
EXPRESSION
DNA
C7
PREVALENCE
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
journal.pone.0233974.pdf 1.117MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot